Summary
Behavioral and molecular methods were used to study and determine whether there is a link between depression that may be a factor in drug/alcohol addiction, and the endocannabinoid hypothesis of substance abuse. Depression is a lack of interest in the pleasurable things of life (termed anhedonia) and depressed mood. It is unknown whether CB2 cannabinoid receptors are expressed in the brain and whether they are involved in depression and substance abuse. Therefore, mice were subjected daily for 4 wk to chronic mild stress (CMS), and anhedonia was measured by the consumption of 2% sucrose solution. Behavioral and rewarding effects of abused substances were determined in the CMS and control animals. The expression of CB2 receptors and their gene transcripts was compared in the brains of CMS and control animals by Western blotting using CB2 receptor antibody and reverse transcriptase-polymerase chain reaction (RT-PCR). Furthermore, the expression and immunocytochemical identification of CB2 cannabinoid receptor in the rat brain were determined. CMS induced gender-specific aversions, which were blocked by WIN55,212-2, a nonspecific CB1 and CB2 cannabinoid receptor agonist. Direct CB2 antisense oligonucleotide microinjection into the mouse brain induced anxiolysis, indicating that CB2 or CB2like receptors are present in the brain and may influence behavior. The major finding from these studies was the expression of CB2 receptor and its gene transcript in the mouse brain, which was enhanced by CMS. These preliminary results, if confirmed, suggest that the CB2 receptors are expressed in the mammalian brain and may be nvolved in depression and substance abuse.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., and Bonner, T. I. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346(6284), 561–564.
Gérard, C., Mollereau, C., Vassart, G., and Parmentier, M. (1990) Nucleotide sequence of a human cannabinoid receptor cDNA. Nucleic Acids Res. 18(23), 7142.
Gérard, C. M., Mollereau, C., Vassart, G., and Parmentier, M. (1991) Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem. J. 279(Pt. 1), 129–134.
Chakrabarti, A., Ekuta, J. E., and Onaivi, E. S. (1998) Neurobehavioral effects of anandamide and cannabinoid receptor gene expression in mice. Brain Res. Bull. 45, 67–74.
Arnone, M., Maruani, J., Chaperon, F., Thiebot, M.H., Poncelet, M., Soubrie, P., and Le Fur, G. (1997) Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl.) 132, 104–106.
Fride, E. (2004) The endocannabinoid-CB receptor system: importance for development and in pediatric disease. Neuro. Endocrinol. Lett. 25, 24–30.
Fride, E., Suris, R., Weidenfeld, J., and Mechoulam, R. (2004) The endocannabinoid system lowers stress response. 2004 Symposium on the Cannabinoids, ICRS, Paestum, Italy 200.
Kearn, C. S. and Hilliard, C. J. (1997) Rat microglial cell express the peripheraltype cannabinoid receptor (CB2) which is negatively coupled to adenylyl cyclase. ICRS 1997 Symposium on Cannabinoids, p. 61.
Facci, L., Dal Toso, R., Romanello, S., Buriani, A., Skaper, S. D., and Leona, A. (1995) Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. PNAS 92, 3376–3380.
Pazos, M. R., Nunez, E., Benito, C., Tolon, R. M., and Romero, J. (2004). Role of the endocannabinoid system in Alzheimer’s disease: new perspectives. Life Sci. 75, 1907–1915.
Skaper, S. D., Buriani, A., Dal Toso, R., Petrelli, L., Rimanello, S., Facci, L., and Leon, A. The AliAmide palmitoylethanolamide and cannabinoids, but not anandamide are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. PNAS 93, 3984–3989.
Benito, C., Nunez, E., Tolon, R. M., Carrier, E. J., Rabano, A., Hillard, C. J., and Romero, J. (2003) Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neurite plaque-associated glia in Alzheimers’s disease brains. J. Neurosci. 23, 11136–11141.
Nunez, E., Benito, C., Pazos, M. R., Barbachano, A., Fajardo, O., Gonzalez, S., Tolon, R. M., and Romero, J. (2004) Cannabinoid CB2 receptors are expressed by perivascular microglia cells in the human brain: an immunohistochemical study. Synapse 53, 208–213.
Griffin G., Wray, E. J., Tao, Q., McAllister S. D., Rorrer, W. K., Aung, M., Martin, B. R, and Abood, M. E. (1999) Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system. Eur. J. Pharmacol. 377, 117–125.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Humana Press Inc.
About this protocol
Cite this protocol
Onaivi, E.S. et al. (2006). Methods to Study the Behavioral Effects and Expression of CB2 Cannabinoid Receptors and Its Gene Transcripts in Chronic Mild Stress Model of Depression. In: Onaivi, E.S. (eds) Marijuana and Cannabinoid Research. Methods In Molecular Medicine™, vol 123. Humana Press. https://doi.org/10.1385/1-59259-999-0:291
Download citation
DOI: https://doi.org/10.1385/1-59259-999-0:291
Publisher Name: Humana Press
Print ISBN: 978-1-58829-350-3
Online ISBN: 978-1-59259-999-8
eBook Packages: Springer Protocols